Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Lost Civilizations
>
Mylan
>
Tax benefits lift Mylan’s quarterly profit
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6049633"]Mylan reported yet another quarter of declining sales, a trend the company has been seeing for the last couple of quarters.</p><p>The sales decline was marred by increased competition and the continuing declining sales of the company’s allergy drug EpiPen, which in turn resulted in a 19% decline in sales in its North America sales.</p><p>Revenue declined 1.2% to $2.68 billion from $2.71 billion a year ago.</p><p>Mylan reported a profit increase of 31% for the quarter to $87.1 million or $0.17 per share, mainly influenced by an income tax benefit of $76.6 million.</p><p>On an adjusted basis, the drug maker reported a 3.22% increase in its earnings per share to $0.96.</p><p><a href="https://news.alphastreet.com/mylan-1q-2018-results/" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://news.alphastreet.com/mylan-1q-2018-results/" rel="nofollow">https://news.alphastreet.com/mylan-1q-2018-results/</a>[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6049633"]Mylan reported yet another quarter of declining sales, a trend the company has been seeing for the last couple of quarters. The sales decline was marred by increased competition and the continuing declining sales of the company’s allergy drug EpiPen, which in turn resulted in a 19% decline in sales in its North America sales. Revenue declined 1.2% to $2.68 billion from $2.71 billion a year ago. Mylan reported a profit increase of 31% for the quarter to $87.1 million or $0.17 per share, mainly influenced by an income tax benefit of $76.6 million. On an adjusted basis, the drug maker reported a 3.22% increase in its earnings per share to $0.96. [URL]https://news.alphastreet.com/mylan-1q-2018-results/[/URL][/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Lost Civilizations
>
Mylan
>
Tax benefits lift Mylan’s quarterly profit
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Lost Civilizations
>
Mylan
>
Tax benefits lift Mylan’s quarterly profit
>